Tag: Immunogenicity
Systemic lupus erythematosus (SLE) is a prototypic chronic, multiorgan autoimmune disease characterized by immune complex deposition and vasculopathy, and, therefore, can affect any organ and tissue of the human body.
Anti-TNF-α therapies are widely used in a variety of inflammatory diseases including rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and inflammatory bowel disease (IBD). This group of drugs includes infliximab, etanercept, adalimumab, and more recently, certolizumab pegol and golimumab. The serious adverse effects of these agents are immunogenicity along with infections and reactivation of tuberculosis.